Editorial: Infliximab induction therapy in pediatric Crohn's disease—A cost‐effective strategy?

Documenti analoghi

• Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply
  di: Stephanie A. Vuijk, et al.
  Pubblicazione: (2024)
• Research Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series
  di: Rahul S. Dalal, et al.
  Pubblicazione: (2025)
• Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras
  di: Daniel Tassone, et al.
  Pubblicazione: (2024)
• Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease?
  di: Konstantinos Papamichael, et al.
  Pubblicazione: (2024)
• Performance of bowel preparation quality scales in patients with Crohn's disease
  di: Virginia Solitano, et al.
  Pubblicazione: (2024)